Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.08USD
9:00pm BST
Change (% chg)

$-0.11 (-2.12%)
Prev Close
$5.19
Open
$5.20
Day's High
$5.20
Day's Low
$5.03
Volume
88,495
Avg. Vol
114,979
52-wk High
$7.67
52-wk Low
$3.68

Latest Key Developments (Source: Significant Developments)

Engaged Capital Reports 5.2 Pct Stake In Aratana Therapeutics Inc, As Of April 4, 2018 SEC Filing
Thursday, 5 Apr 2018 

April 5 (Reuters) - Aratana Therapeutics Inc ::SEC FILING.ENGAGED CAPITAL LLC SAYS PURCHASED ARATANA THERAPEUTICS' SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE UNDERVALUED.ENGAGED CAPITAL LLC SAYS HAS ENGAGED, TO CONTINUE TO ENGAGE, IN COMMUNICATIONS WITH ARATANA THERAPEUTICS BOARD FOR MEANS TO CREATE STOCKHOLDER VALUE.ON MARCH 23, DELIVERED LETTER TO ARATANA THERAPEUTICS NOMINATING CRAIG BARBAROSH, ERIC ENDE, LOWELL ROBINSON FOR ELECTION TO BOARD ‍​.  Full Article

Aratana Therapeutics Reports Q4 Loss Per Share $0.37
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.37.Q4 REVENUE $10.4 MILLION VERSUS $292,000.Q4 2017 NET LOSS INCLUDED $7.4 MILLION OF IMPAIRMENT CHARGES FOR INTANGIBLE ASSETS.EXPECTS ABOUT $35.0 MILLION OF CASH TO BE USED FOR ON-GOING OPERATIONS IN 2018.Q4 EARNINGS PER SHARE VIEW $-0.21, REVENUE VIEW $6.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Aratana Therapeutics Expands Therapeutic Candidate Pipeline
Thursday, 1 Mar 2018 

March 1 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE.ARATANA THERAPEUTICS INC - ANNOUNCED AN ANIMAL HEALTH RESEARCH AND DEVELOPMENT COLLABORATION WITH ASKAT INC.ARATANA THERAPEUTICS INC - LICENSED EXCLUSIVE, WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE AT-019, KNOWN AS AAT-008 BY ASKAT.ARATANA THERAPEUTICS INC - AT-019 LICENSE AGREEMENT INCLUDES AN UPFRONT PAYMENT OF $0.5 MILLION; MILESTONE PAYMENTS OF UP TO $15.5 MILLION.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY.ARATANA THERAPEUTICS - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS - PARTNER RESPONSIBLE FOR AT-016 SHARED RESULTS OF PIVOTAL STUDY, WHICH DID NOT ACHIEVE PROTOCOL-DEFINED EFFICACY SUCCESS CRITERIA.ARATANA THERAPEUTICS INC - AS PART OF CO'S EXCLUSIVE COMMERCIAL LICENSE FOR DOGS WITH OSTEOARTHRITIS IN U.S., CO FUNDED CLINICAL STUDY & OTHER WORK.ARATANA THERAPEUTICS - CO ANTICIPATES AFTER PARTNER EVALUATED STUDY RESULTS, PARTIES TO DETERMINE IF COLLABORATION TO BRING THERAPEUTIC TO MARKET TO CONTINUE.  Full Article

Aratana Therapeutics Announces Proposed Public Offering
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Aratana Therapeutics reports Q3 loss per share of $0.21
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $6.2 million.  Full Article

Aratana Therapeutics announces launch of Entyce
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution).Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs​.  Full Article

Aratana Therapeutics files for mixed shelf offering of up to $100 mln
Friday, 4 Aug 2017 

Aug 4 (Reuters) - Aratana Therapeutics Inc :Aratana therapeutics inc files for mixed shelf offering of up to $100 million - sec filing‍​.  Full Article